Ocugen (NASDAQ:OCGN) is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to discovering, developing and commercializing innovative therapies for rare and underserved diseases. The company’s strategic focus lies in ophthalmology and immunology, with an emphasis on gene therapies to address inherited retinal disorders and vaccines to combat infectious diseases.
Ocugen’s pipeline is anchored by a suite of gene therapy candidates designed to treat inherited retinal degenerations such as Leber congenital amaurosis, retinitis pigmentosa and geographic atrophy secondary to age-related macular degeneration. These programs leverage proprietary adeno-associated virus (AAV) vector platforms engineered for efficient retinal gene delivery and sustained transgene expression. In addition to ocular gene therapies, Ocugen has advanced vaccine development through its partnership with Bharat Biotech, securing U.S. rights to Covaxin, a whole-virion COVID-19 vaccine.
In June 2022, the U.S. Food and Drug Administration granted emergency use authorization for Covaxin, enabling Ocugen to oversee its manufacture, distribution and commercialization in North America. Beyond the COVID-19 vaccine program, the company continues to explore additional therapeutic applications of its platform technologies, including non-infectious and systemic ophthalmic conditions, underscoring its commitment to addressing significant unmet medical needs.
Founded in 2013, Ocugen maintains research facilities in Malvern and a collaboration office in Toronto, Canada, supporting both preclinical and clinical development activities. The company’s leadership team brings together veteran executives and scientists with extensive experience at leading biopharmaceutical organizations, spanning gene therapy research, regulatory affairs and commercial operations. Ocugen aims to leverage its dual focus on genetic medicines and vaccines to advance transformative treatments for patients worldwide.
